Rakuten Securities Inc. Sells 13,541 Shares of Tempus AI, Inc. $TEM

Rakuten Securities Inc. trimmed its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 59.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,252 shares of the company’s stock after selling 13,541 shares during the quarter. Rakuten Securities Inc.’s holdings in Tempus AI were worth $546,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Renaissance Capital LLC grew its stake in Tempus AI by 26.9% during the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after acquiring an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in Tempus AI in the 3rd quarter worth $1,695,000. Vanguard Group Inc. lifted its stake in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Finally, Krane Funds Advisors LLC boosted its holdings in shares of Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TEM shares. HC Wainwright raised their price objective on Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Jefferies Financial Group assumed coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target for the company. BTIG Research cut their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, Guggenheim reduced their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and an average target price of $71.36.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $51.44 on Friday. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The stock has a market capitalization of $9.20 billion, a P/E ratio of -36.48 and a beta of 4.90. The firm has a fifty day simple moving average of $50.87 and a two-hundred day simple moving average of $65.13. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Erik Phelps sold 9,464 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total value of $562,445.52. Following the sale, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 563,841 shares of company stock worth $32,258,311 in the last quarter. Company insiders own 24.26% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.